ReviewGenes & diseases2026
MicroRNA-23b: Roles, functions and mechanisms in tumor.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- WISP-3 promotes tumor-monocyte adhesion through a MEK/ERK-dependent miR-12131/ICAM-4 axis in lung adenocarcinoma.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs are a class of non-coding short-stranded RNAs with important biological roles as post-transcriptional regulators of gene expression, involved in a variety of biological processes, such as cell growth, apoptosis, and angiogenesis. miR-23b, a well-studied miRNA, is aberrantly expressed in a variety of cancers. In this paper, we used the literature review method to sort out the biological roles and regulation of miR-23b in different types of cancers, including digestive system cancers, reproductive system cancers, head and neck cancers, genitourinary system cancers, and lung cancers. The data show that miR-23b can target both oncogenes and tumor suppressors, and its expression regulation in different types of cancers shows heterogeneity, which mainly acts through affecting signaling pathways, such as Wnt/β-catenin for tumorigenesis, and apoptotic proteins, such as BCL2 or oncogenes. The expression of miR-23b is closely related to the overall survival rate, disease-free survival rate, and prognosis in many cancers. Meanwhile, various
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.